Tonix rais­es $144M in a di­rect of­fer­ing fol­low­ing pos­i­tive PhI­II da­ta for its fi­bromyal­gia drug

Tonix Phar­ma­ceu­ti­cals said it’s rais­ing $144 mil­lion in a di­rect of­fer­ing that in­cludes $30 mil­lion up­front on the same day that it re­leased da­ta from a Phase III study show­ing its fi­bromyal­gia drug met the pri­ma­ry end­point.

The bio­phar­ma is is­su­ing about 54 mil­lion shares of its com­mon stock and Se­ries C and D reg­is­tered war­rants to pur­chase an ag­gre­gate of 162.1 mil­lion shares of com­mon stock. It plans to use the funds raised to pre­pare the NDA for its fi­bromyal­gia drug in the sec­ond half of 2024.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER